Bicara Therapeutics (BCAX) to Release Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $13.00 on Monday. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The company’s 50-day moving average is $14.40.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target for the company. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Finally, HC Wainwright raised their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.